Burke TA - Search Results

1

The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus.

Burke TA, Sturkenboom MC, Ohman-Strickland PA, Wentworth CE, Rhoads GG. Burke TA, et al. Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):979-87. doi: 10.1002/pds.1444. Pharmacoepidemiol Drug Saf. 2007. PMID: 17605137

2

Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice.

Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Burke TA, et al. J Hypertens. 2006 Jun;24(6):1193-200. doi: 10.1097/01.hjh.0000226211.95936.f5. J Hypertens. 2006. PMID: 16685222

3

Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice.

Phatak H, Wentworth C, Sazonov V, Burke T. Phatak H, et al. Atherosclerosis. 2009 Jan;202(1):225-33. doi: 10.1016/j.atherosclerosis.2008.03.016. Epub 2008 Mar 27. Atherosclerosis. 2009. PMID: 18457840

4

Dosage, titration, and gaps in treatment with extended release niacin in clinical practice.

Kamal-Bahl SJ, Burke TA, Watson DJ, Wentworth CE. Kamal-Bahl SJ, et al. Among authors: burke ta. Curr Med Res Opin. 2008 Jun;24(6):1817-21. doi: 10.1185/03007990802083408. Epub 2008 May 15. Curr Med Res Opin. 2008. PMID: 18485268

5

Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs.

Sturkenboom MC, Burke TA, Tangelder MJ, Dieleman JP, Walton S, Goldstein JL. Sturkenboom MC, et al. Among authors: burke ta. Aliment Pharmacol Ther. 2003 Dec;18(11-12):1137-47. doi: 10.1046/j.1365-2036.2003.01795.x. Aliment Pharmacol Ther. 2003. PMID: 14653834

6

Underutilization of preventive strategies in patients receiving NSAIDs.

Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL. Sturkenboom MC, et al. Among authors: burke ta. Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii23-31. doi: 10.1093/rheumatology/keg495. Rheumatology (Oxford). 2003. PMID: 14585915

7

Application of a propensity score to adjust for channelling bias with NSAIDs.

Morant SV, Pettitt D, MacDonald TM, Burke TA, Goldstein JL. Morant SV, et al. Among authors: burke ta. Pharmacoepidemiol Drug Saf. 2004 Jun;13(6):345-53. doi: 10.1002/pds.946. Pharmacoepidemiol Drug Saf. 2004. PMID: 15170763

8

Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.

Zhao SZ, Wentworth C, Burke TA, Makuch RW. Zhao SZ, et al. Among authors: burke ta. Pharmacoepidemiol Drug Saf. 2004 May;13(5):277-87. doi: 10.1002/pds.909. Pharmacoepidemiol Drug Saf. 2004. PMID: 15133778

9

Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Zhao SZ, et al. Among authors: burke ta. Am J Manag Care. 2002 Oct;8(15 Suppl):S401-13. Am J Manag Care. 2002. PMID: 12416790 Free article.

10

Lipid testing among patients beginning statin therapy in general practice in the United Kingdom.

Phatak H, Wentworth C, Burke TA. Phatak H, et al. Among authors: burke ta. Value Health. 2008 Sep-Oct;11(5):933-8. doi: 10.1111/j.1524-4733.2008.00345.x. Epub 2008 May 16. Value Health. 2008. PMID: 18489501 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters